Replies to post #128740 on ORIONS Money Stocks

[alfaspider]

I've not gone back into CFW- seems like lots of debt there? and after CEO forced out run by a hedge fund to pay off the banks?

Have you looked at ELON?

[read_this_n0w]

What an utter self serving crap again by those oil traders:

"There is little in the way of solid evidence that oil demand growth has slowed down from the unsustainably high pace of growth seen in 2010," Barclays Capital said in a report. "

ye right... 2010 saw many profits jump tens of percentages as well, not because profits rose that much but because they were so darn low in 2009

same for oil consumption most likely, logic prevails


Saudi Arabia commented few days ago that they did see a slowdown in demand.

[read_this_n0w]

Watch OXGN break 8ema.

OXGN Oxigene Nears Marketing Approval of First Anaplastic Thyroid Cancer Drug

http://www.themarketfinancial.com/oxigene-nears-marketing-approval-of-first-anaplastic-thyroid-cancer-drug/126154


With just a few weeks left on the calendar before the world’s largest oncology annual meeting, investors are already gearing up their portfolios for equities that could see exponential gains based on their potentially new research abstracts. The American Society of Clinical Oncology (ASCO) will begin on June 3rd and will feature everything from investigational new drugs to well developed late-stage products. While many companies have seen strong share appreciation leading up to their presentations, the real key lies in finding companies like Oxigene (NASDAQ:OXGN) which has yet to experience this momentum and mass media coverage.

At a market cap of only 10M, Oxigene remains the cheapest and most undervalued of all phase 3 late-stage oncology companies worldwide, with its flagship product, ZYBRESTAT targeting Tanaplastic Thyroid Cancer. The company has stated that they will be presenting the final phase 2/3 (FACT study) data for the drug at the ASCO, and many experts seem to be leaning towards highly positive results based on its previous clinical trials. Currently there exists no treatments available for this form of cancer other than radiation therapy and surgery which is usually combined with chemotherapy.

Just a few months ago, the company reported positive data from the FACT study of ZYBRESTAT plus chemotherapy in patients with Anaplastic thyroid cancer (ATC). At the 14th International Thyroid Congress, the company’s investigators reported that patients receiving ZYBRESTAT had a median overall survival (OS) time of 5.1 months, compared with a median survival time of 4.1 months for patients receiving chemotherapy alone. Furthermore, 48% of patients treated with ZYBRESTAT and chemotherapy were alive at six months, compared with 37% percent of patients treated with only chemotherapy and at one year, 23% of patients treated with ZYBRESTAT and chemotherapy were alive compared to 9% of patients treated with chemotherapy alone. These are some of the best results of any late-stage Aanaplastic thyroid cancer drugs seen worldwide, and this improvement in OS is meaningful, both clinically and on a personal level for patients. With no currently approved drugs in the market for treatment, the doors are wide open for Oxigene to step in and dominate it. The company also reported on March 21st that they had spoken with the FDA and received very positive type C meeting minutes stating that the trial data was highly suggestive of regulatory approval given an additional clinical trial with a suvival endpoint.

The Thyroid cancer market was estimated to be worth $55M in 2010, and is expected to grow at a CAGR (Compound Annual Growth Rate) of 27.34% to reach $298M by 2017.

Oxigene will also be presenting their additional phase 2 (FALCON study) data also for ZYBRESTAT for the treatment of Non-small cell lung cancer at the ASCO. The FALCON study is the first randomized, controlled study of a vascular disrupting agent (VDA) in combination with an anti-angiogenic agent, and combined both bevacizumab and chemotherapy. In mid-2010, the company reported that to date, the drug was well-tolerated, and the clinical activity they are seeing indicates a trend toward clinical benefit. These data are still interim; and the final overall survival data from this study will be presented at the ASCO.

According to a new report by Global Industry Analysts, the global Non-small cell lung cancer therapeutics market is slated to reach $13.3 billion by 2015. This is largely fueled by rising incidence of lung cancer, improved understanding of non-small cell lung cancer, and the development of new treatments targeted at growth factor pathways.